Skip to navigation Skip to content
  • The Cancer Letter on Facebook
  • The Cancer Letter on Twitter
  • The Cancer Letter on LinkedIn

The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
  • SUBSCRIBE
  • Login
  • SUBSCRIBE
  • Login
The Cancer Letter
Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
The Cancer Letter's weekly podcast of interviews, discussions, and more to dig deep into the issues that shape oncology.
New episodes every Wednesday.
SUBSCRIBE ON
Spotify Apple Podcast YouTube
Spotify Apple Podcast YouTube
on air
In The Headlines: George Weiner on the importance of patients’ stories
Podcast

In The Headlines: George Weiner on the importance of patients’ stories

July 09, 2025
Vol.51 No.26
In the Headlines: MD Anderson’s Pisters on doing “something gigantic for pediatric cancer”
Podcast

In the Headlines: MD Anderson’s Pisters on doing “something gigantic for pediatric cancer”

July 02, 2025
Vol.51 No.25
In the Headlines: What if curing diseases was treated like a business?
Podcast

In the Headlines: What if curing diseases was treated like a business?

June 25, 2025
Vol.51 No.24
In the Headlines: Missing record of NCAB meetings restored to NIH website
Podcast

In the Headlines: Missing record of NCAB meetings restored to NIH website

June 18, 2025
Vol.51 No.23
The Directors: Candace Johnson and Jonathan Friedberg on living through uncertainty at NCI, payment woes
PodcastThe Directors

The Directors: Candace Johnson and Jonathan Friedberg on living through uncertainty at NCI, payment woes
Directors of two neighboring cancer centers in Upstate New York will face challenges, but “we’ll get through it”

June 13, 2025
Vol.51 No.23
By Paul Goldberg
In The Headlines: Increasing incidence of early-onset cancer is “a paradigm shift oncology isn’t quite prepared for”
Podcast

In The Headlines: Increasing incidence of early-onset cancer is “a paradigm shift oncology isn’t quite prepared for”

June 11, 2025
Vol.51 No.22
In The Headlines: Kimryn Rathmell, ASCO, and “an important time in cancer research”
Podcast

In The Headlines: Kimryn Rathmell, ASCO, and “an important time in cancer research”

June 04, 2025
Vol.51 No.21
In The Headlines: Back to “business as usual” at FDA?
Podcast

In The Headlines: Back to “business as usual” at FDA?

May 28, 2025
Vol.51 No.20
In The Headlines: Wafik El-Deiry on how “America First” means investing in NCI
Podcast

In The Headlines: Wafik El-Deiry on how “America First” means investing in NCI

May 21, 2025
Vol.51 No.19
The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
PodcastThe Directors

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”

May 16, 2025
Vol.51 No.19
By Katie Goldberg

Posts navigation

Previous1…7891011Next

Trending Stories

  • As daraxonrasib hits the clinic, Frank McCormick says RAS is bigger than pancreatic cancer
  • Is it time to re-assess the practice and practicality of screening colonoscopy?
    Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives
  • From “default dead” to living the future of cancer care
    As founding CEO of GitLab, I went “founder mode” on my osteosarcoma
  • Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
  • Cancer leaders play “musical chairs” as executive jobs fill at top cancer centers
    Lee replaces Pisters at MD Anderson, Tuveson moves to Duke, and Mitchell is named director at University of Florida
  • mRNA vaccine for melanoma is hailed as a turning point in medicine
    The data from Moderna and Merck’s trial have yet to be presented

ABOUT
ABOUT
About The Cancer Letter
Accessibility Statement
Our Contributors
Editorial policies
Store
SUBSCRIPTIONS
SUBSCRIPTIONS
Our readers
Pricing
News alerts
About IP login
Job board
CONTACT
CONTACT
Contact us
Submission guidelines
Advertise
Careers
SEE ALSO
Cancer History Project
The Cancer Letter
Copyright © 2026 The Cancer Letter Inc. All rights reserved.
Privacy Policy
Terms & Conditions
FOLLOW US
Instagram
Twitter
LinkedIn
Facebook
Vimeo
Scroll to top
Request Cancellation

Subscription Change

This change will be effective immediately and your card will be charged a prorated amount based on your existing subscription level.

OK Cancel

Renew today!

Your subscription has lapsed. Subscribe today to access this content.
SUBSCRIBE NOW

Subscriber content

Log in or subscribe to access The Cancer Letter.
LOGINSUBSCRIBE NOW
SEARCH DATE
SEARCH TEXT
      Cancel
      OK
      Cancel
      OK
      Delete Account
      Are you sure you want to delete your account? This will erase all of your account data from the site. To delete your account enter your password below
      No

      Never miss an issue!

      Get alerts for our award-winning coverage in your inbox.

      Login

       
      Forgot Password?

      Site license subscribers:
      Log in with your IP | Register a sponsored account